Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1099-1107

  Faletto, Michael B ^a,b   Miller, Wayne H ^a   Garvey, Edward P ^a   St Clair, Marty H ^a   Daluge, Susan M ^a   Good, Steven S ^a  

^a GLAXOSMITHKLINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ABACAVIR; CARBOVIR; MYCOPHENOLIC ACID; PHOSPHOTRANSFERASE; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG METABOLISM; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 0030903443     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1099     Document Type: Article

References (50)

1. Agarwal, R. P. 1982. Inhibitors of adenosine deaminase. Pharm. Ther. 17: 399-429.
2. Allison, A. C., W. J. Kowalski, C. D. Muller, and E. M. Eugui. 1993. Mechanisms of action of mycophenolic acid. Ann. N. Y. Acad. Sci. 696:63-87.
3. Balzarini, J. 1994. Metabolism and mechanism of action of purine and pyrimidine derivatives. Pharm. World Sci. 16:113-126.
4. Bondoc, L. L., Jr., W. M. Shannon, J. A. Secrist III, R. Vince, and A. Fridland. 1990. Metabolism of the carbocyclic nucleoside analogue carbovir, an inhibitor of human immunodeficiency virus, in human lymphoid cells. Biochemistry 29:9839-9843.
5. Bondoc, L. L., Jr., B. L. Robbins, G. S. Ahluwalia, H. Mitsuya, D. G. Johns, and A. Fridland. 1991. Modulation of metabolism and anti-HIV-1 activity of purine 2′,3′-dideoxynucleosides by IMP dehydrogenase inhibitors. Adv. Exp. Med. Biol. 309A:49-53.
6. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
7. Brouwer, K. R., R. L. St. Claire, J. Lagarde, J. E. Patanella, J. S. Walsh, and G. T. Miwa. 1990. The pharmacokinetics of (-)-carbovir in rats: evidence for nonlinear elimination. Drug Metab. Dispos. 18:1078-1083.
8. Ching, S. V., K. M. Ayers, R. E. Dornsife, G. L. Grebe, and J. L. Howard. 1994. Nonclinical toxicology and in vitro toxicity studies with the novel anti-HIV agent (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate, abstr. I88, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Daluge, S. M., S. S. Good, M. T. Martin, S. R. Tibbels, W. H. Miller, D. R. Averett, M. H. St. Clair, and K. M. Ayers. 1994. 1592U89 succinate - a novel carbocyclic nucleoside analogue with potent, selective anti-HIV activity, abstr. I6, p. 7. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Daluge, S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
11. Daluge, S. M., D. J. M. Purifoy, P. M. Savina, M. H. St. Clair, N. R. Parry, I. K. Dev, P. Novak, K. M. Ayers, J. E. Reardon, G. B. Roberts, J. A. Fyfe, M. R. Blum, D. R. Averett, R. E. Dornsife, B. A. Domin, R. Ferone, D. A. Lewis, and T. A. Krenitsky. 1994. 5-Chloro-2′,3′-dideoxy-3′-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 38:1590-1603.
12. De Clercq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses 8:19-134.
13. Dornsife, R. E., M. H. St. Clair, A. T. Huang, T. J. Panella, G. W. Koszalka, C. L. Burns, and D. R. Averett. 1991. Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob. Agents Chemother. 35:322-328.
14. Faletto, M. B., W. H. Miller, E. P. Garvey, J. E. Reardon, and S. S. Good. 1994. Unique intracellular activation of a new anti-HIV agent (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) in the human T-lymphoblastoid cell line CEM-T4, abstr. I84, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, R. J. Hazen, S. M. Daluge, and S. S. Good. 1995. Unique purine crossover pathway for the potent anti-HIV agent 1592U89. Antiviral Res. 26:A262.
16. Fleischer, S., and M. Kervina. 1974. Subcellular fractionation of rat liver. Methods Enzymol. 31:6-41.
17. Frieden, C., H. R. Gilbert, W. H. Miller, and R. L. Miller. 1979. Adenylate deaminase: potent inhibition by 2′-deoxycoformycin 5′-phosphate. Biochem. Biophys. Res. Commun. 91:278-283.
18. Frieden, C., L. C. Kurz, and H. R. Gilbert. 1980. Adenosine deaminase and adenylate deaminase: comparative kinetic studies with transition state and ground state analog inhibitors. Biochemistry 19:5303-5309.
19. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. Nusinoff Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337.
20. Furman, P. A., and D. W. Barry. 1988. Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am. J. Med. 85(Suppl. 2A):176-181.
21. Furman, P. A., M. Davis, D. C. Liotta, M. Paff, L. W. Frick, D. J. Nelson, R. E. Dornsife, J. A. Wurster, L. J. Wilson, J. A. Fyfe, J. V. Tuttle, W. H. Miller, L. Condreay, D. R. Averett, R. F. Schinazi, and G. R. Painter. 1992. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:2686-2692.
22. Garvey, E., and T. A. Krenitsky. 1992. A novel human phosphotransferase highly specific for adenosine. Arch. Biochem. Biophys. 296:161-169.
23. Good, S. S., B. S. Owens, M. B. Faletto, W. B. Mahony, and B. A. Domin. 1994. Disposition in monkeys and mice of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate, a potent inhibitor of HIV, abstr. I86, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Hao, Z., D. A. Cooney, N. R. Hartman, D. R. Perno, A. Fridland, A. L. DeVico, M. G. Sarngadharan, S. Broder, and D. G. Johns. 1988. Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol. Pharmacol. 34:431-435.
25. Hartman, N. R., G. S. Ahluwalia, D. A. Cooney, H. Mitsuya, S. Kageyama, A. Fridland, S. Broder, and D. G. Johns. 1991. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol. Pharmacol. 40:118-124.
26. Huang, S.-H., R. P. Remmel, and C. L. Zimmerman. 1991. The bioavailability and nonlinear clearance of (-)-carbovir in the rat. Pharm. Res. 8:739-743.
27. Johnson, M. A., and A. Fridland. 1989. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36:291-295.
28. Lowe, D. M., W. K. Alderton, M. R. Ellis, V. Parmar, W. H. Miller, G. B. Roberts, J. A. Fyfe, R. Gaillard, P. Ertl, W. Snowden, and E. Littler. 1995. Mode of action of (R)-9-[4-hydroxymethyl-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob. Agents Chemother. 39:1802-1808.
29. Mahony, W. B., B. A. Domin, S. M. Daluge, W. H. Miller, and T. P. Zimmerman. 1992. Enantiomeric selectivity of carbovir transport. J. Biol. Chem. 267:19792-19797.
30. + CEM cells. Proc. Am. Assoc. Cancer Res. 36:2211. (Abstract.)
31. Marr, C. L. P., and C. R. Penn. 1992. Stability of carbovir, a potent inhibitor of HIV, to phosphorolysis by human purine nucleoside phosphorylase. Antiviral Chem. Chemother. 3:121-124.
32. Miller, R. L., D. L. Adamczyk, and W. H. Miller. 1979. Adenosine kinase from rabbit liver. 1. Purification by affinity chromatography and properties. J. Biol. Chem. 254:2339-2345.
33. Miller, W. Unpublished results.
34. Miller, W. H., S. M. Daluge, E. P. Garvey, S. Hopkins, J. E. Reardon, F. L. Boyd, and R. L. Miller. 1992. Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity. J. Biol. Chem. 267:21220-21224.
35. Mitsuya, H., R. Yarchoan, S. Kageyama, and S. Broder. 1991. Targeted therapy of human immunodeficiency virus-related disease. FASEB J. 5: 2369-2381.
36. Orr, D. C., H. T. Figueiredo, C.-L. Mo, C. R. Penn, and J. M. Cameron. 1992. DNA chain termination activity and inhibition of human immunodeficiency virus reverse transcriptase by carbocyclic 2′,3′-dideoxyguanosine triphosphate. J. Biol. Chem. 267:4177-4182.
37. Parker, W. B., E. L. White, S. C. Shaddix, L. J. Ross, R. W. Buckheit, Jr., J. M. Germany, J. A. Secrist III, R. Vince, and W. M. Shannon. 1991. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymcrases α, β, and γ by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine, and 3′-deoxythymidine. J. Biol. Chem. 266:1754-1762.
38. Parker, W. B., S. C. Shaddix, B. J. Bowdon, L. M. Rose, R. Vince, W. M. Shannon, and L. L. Bennett, Jr. 1993. Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism. Antimicrob. Agents Chemother. 37:1004-1009.
39. Prus, K. L. (Glaxo Wellcome Inc., Research Triangle Park, N.C.). Personal communication.
40. Rundell, K. W., P. C. Tullson, and R. L. Terjung. 1992. Altered kinetics of AMP deaminase by myosin binding. Am. J. Physiol. 263:C294-C299.
41. Siaw, M. F. E., and M. S. Coleman. 1984. In vitro metabolism of deoxycoformycin in human T lymphoblastoid cells. J. Biol. Chem. 259:9426-9433.
42. Spector, T., T. E. Jones, and L. M. Beacham III. 1983. Conversion of 2,6-diamino-9-(2-hydroxyethoxymethyl)purine to acyclovir as catalyzed by adenosine deaminase. Biochem. Pharmacol. 32:2505-2509.
43. Tisdale, M., T. Alnadof, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
44. Tisdale, M., N. R. Parry, D. Cousens, M. H. St. Clair, and L. R. Boone. 1994. Anti-HIV activity of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89), abstr. I82, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
45. Trennery, P. (Medicines Safety Evaluation, Glaxo Wellcome plc, Ware, United Kingdom). Personal communication.
46. Tuttle, J. V., and T. A. Krenitsky. 1984. Effects of acyclovir and its metabolites on purine nucleoside phosphorylase. J. Biol. Chem. 259:4065-4069.
47. Venner, P. M., and R. I. Glazer. 1979. The metabolism of 2′-deoxycoformycin by L1210 cells in vitro. Biochem. Pharmacol. 28:3239-3242.
48. Vince, R., M. Hua, J. Brownell, S. Daluge, F. Lee, W. M. Shannon, G. C. Lavelle, J. Qualls, O. S. Weislow, R. Kiser, P. G. Canonico, R. H. Schultz, V. L. Narayanan, J. G. Mayo, R. H. Shoemaker, and M. R. Boyd. 1988. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem. Biophys. Res. Commun. 156:1046-1053.
49. Vince, R., and J. Brownell. 1990. Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-)-enantiomer. Biochem. Biophys. Res. Commun. 168:912-916.
50. White, E. L., W. B. Parker, L. J. Macy, S. C. Shaddix, G. McCaleb, J. A. Secrist III, R. Vince, and W. M. Shannon. 1989. Comparison of the effect of carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem. Biophys. Res. Commun. 161:393-398.